Skip to main content
SpringerLink
Log in

Progress in Hepatocellular Carcinoma Treatment

  • Conference proceedings
  • © 2000

Overview

Editors:
  1. Kiwamu Okita

    1. First Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • New therapeutic modalities in hepatocelluar carcinoma

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (12 papers)

  1. Front Matter

    Pages II-XI
    Download chapter PDF

  2. The Efficacy of the Ultrasonographic Screening Test for Early Detection of Hepatocellular Carcinoma and Risk Factors of HCC in Korea

    • Kwang-Hyub Han, Jeong Il Jeong, Sang Hoon Ahn, Dong Kee Kim, Chae Yoon Chon, Young Myoung Moon
    Pages 1-9

  3. Percutaneous Ethanol Injection Therapy, Percutaneous Infarction Therapy, and Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma

    • Shuichiro Shiina, Takuma Teratani, Masatoshi Imamura, Shuntaro Obi, Shinpei Sato, Yukihiro Koike et al.
    Pages 10-16

  4. Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma

    • Toshihito Seki, Taiichi Nakagawa, Toru Tamai, Masato Imamura, Akira Nishimura, Noriyo Yamashiki et al.
    Pages 17-22

  5. Percutaneous Ablation of Hepatocellular Carcinoma

    • Tito Livraghi
    Pages 23-34

  6. Treatment with Subsegmental Transcatheter Arterial Embolization for Hepatocellular Carcinoma: Prognosis, Recurrence, and Effect on Liver Function

    • Yukihiro Shirota, Taro Yamashita, Shuichi Terasaki, Eiki Matsushita, Takeshi Urabe, Shuichi Kaneko et al.
    Pages 35-39

  7. Clinical Significance of Liposome-Encapsulated OK-432 Injection with Simultaneous Interventional Radiological Treatment of Hepatocellular Carcinoma Based on Experimental Analysis of Liver-Associated Lymphocytes

    • Takafumi Ichida, Satoshi Yamagiwa, Kazunari Sato, Satoshi Sugahara, Kazuhiro Uehara, Tohru Ishikawa et al.
    Pages 40-48

  8. Phase II Trial of Hepatic Arterial Infusion Chemotherapy Using Cisplatin and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma

    • Masatoshi Tanaka, Eiji Ando, Sigeru Yutani, Kazuta Fukumori, Ryoko Kuromatsu, Yoshihiro Shimauchi et al.
    Pages 49-55

  9. Surgical Treatment of Hepatocellular Carcinoma

    • Masaaki Oka, Minekatsu Nishida, Yoshitaka Maeda
    Pages 56-63

  10. Transjugular Intrahepatic Portosystemic Shunt for Patients with Hepatocellular Carcinoma

    • Kenji Nakamura, Sumio Takashima, Toshio Kaminou, Youichi Kohda, Masao Hamuro, Seisho Hayashi et al.
    Pages 64-75

  11. Prevention of Hepatocarcinogenesis by Fibrosuppression

    • Isao Sakaida, Koji Hironaka, Kiwamu Okita
    Pages 76-85

  12. Cancer Vaccination by B7-1-Transfected Hepatocellular Carcinoma Cells

    • Tomohide Tatsumi, Tetsuo Takehara, Yutaka Sasaki, Masatsugu Hori, Norio Hayashi
    Pages 86-96

  13. Clonal Deletion, A Novel Strategy of Cancer Control that Falls Between Cancer Chemoprevention and Cancer Chemotherapy: A Clinical Experience in Liver Cancer

    • Hisataka Moriwaki, Masataka Okuno, Yoshimune Shiratori, Ichiro Yasuda, Yasutoshi Muto
    Pages 97-103

  14. Back Matter

    Pages 105-107
    Download chapter PDF
Back to top

Keywords

About this book

According to a recent report from the Japanese Ministry of Health and Welfare, the mortality rate for hepatocellular carcinoma (HCC) is more than 30 per 100000 pop­ ulation. In addition,epidemiologists predictan increase in this figure by the year 2015, because of the rather high incidence of chronic liver diseases caused by HCY. The same situation has been observed in other Asian countries. It seems that HCC is likely to be an endemic disease, because of the higher preva­ lence of chronic hepatitis and liver cirrhosis caused by HBV, HCV, and/or aflatoxins in Asian and African countries. We also note that an interesting paper appeared in a recent issue of the New England Journal of Medicine describing the increase in younger HCC patients in the United States as compared with past decades. At present, silent hepatitis C infection is now smoldering in 4 million mostly unsuspecting Americans. Those carriers will be candidates for chronic liver disease, which is a pre­ disposing factor for the development of HCC. In Europe there are an estimated 5 million carriers. Accordingly, it is important to do all we can to reduce the prevalence of HCC not only in African and Asian countries, but also in the United States and Europe. With this perspective,last year the Japanese Society for Hepatology, in cooperation with the Ministry of Health and Welfare, initiated a national campaign to fight HCC.

Editors and Affiliations

  • First Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan

    Kiwamu Okita

Bibliographic Information

  • Book Title: Progress in Hepatocellular Carcinoma Treatment

  • Editors: Kiwamu Okita

  • DOI: https://doi.org/10.1007/978-4-431-67913-4

  • Publisher: Springer Tokyo

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Japan 2000

  • Hardcover ISBN: 978-4-431-70257-3Published: 01 December 1999

  • Softcover ISBN: 978-4-431-67983-7Published: 23 October 2012

  • eBook ISBN: 978-4-431-67913-4Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: XI, 107

  • Topics: Hepatology

Publish with us

Policies and ethics

Back to top

Search

Navigation